Durata Completes $68M IPO; Prices Below Target Range
BioWorld Insight Editor
Further evidence that the post-Facebook initial public offering (IPO) jitters seem to have dissipated, and that the environment for biotech IPOs continues to improve comes with Thursday's debut of venture-backed Durata Therapeutics Inc., of Morristown, N.J. The company priced its initial public offering of 7.5 million shares of common stock at a price of $9 per share.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST